Identification

Name
Piretanide
Accession Number
DB02925  (EXPT03308)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
HOE 118 / HOE-118 / S 73 4118 / S-73-4118
International/Other Brands
Arelix / Piretanide (JAN)
Categories
UNII
DQ6KK6GV93
CAS number
55837-27-9
Weight
Average: 362.4
Monoisotopic: 362.093642386
Chemical Formula
C17H18N2O5S
InChI Key
UJEWTUDSLQGTOA-UHFFFAOYSA-N
InChI
InChI=1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)
IUPAC Name
4-phenoxy-3-(pyrrolidin-1-yl)-5-sulfamoylbenzoic acid
SMILES
NS(=O)(=O)C1=CC(=CC(N2CCCC2)=C1OC1=CC=CC=C1)C(O)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
USolute carrier family 12 member 1
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Piretanide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Piretanide.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Piretanide.Experimental, Illicit
AceclofenacAceclofenac may decrease the diuretic activities of Piretanide.Approved, Investigational
AcemetacinAcemetacin may decrease the diuretic activities of Piretanide.Approved, Experimental, Investigational
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the diuretic activities of Piretanide.Approved, Vet Approved
AclarubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Aclarubicin.Investigational
AdapaleneAdapalene may decrease the diuretic activities of Piretanide.Approved
AlclofenacAlclofenac may decrease the diuretic activities of Piretanide.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Piretanide.Approved
AlcuroniumPiretanide may decrease the neuromuscular blocking activities of Alcuronium.Experimental
AldosteroneAldosterone may increase the hypokalemic activities of Piretanide.Experimental, Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Piretanide.Approved, Illicit
AllopurinolThe risk or severity of adverse effects can be increased when Piretanide is combined with Allopurinol.Approved
AlminoprofenAlminoprofen may decrease the diuretic activities of Piretanide.Experimental
AloxiprinAloxiprin may decrease the diuretic activities of Piretanide.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Piretanide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Piretanide.Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Piretanide.Approved
AmikacinThe risk or severity of adverse effects can be increased when Piretanide is combined with Amikacin.Approved, Vet Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the diuretic activities of Piretanide.Approved
AmrubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Amrubicin.Approved, Investigational
AndrographolideAndrographolide may decrease the diuretic activities of Piretanide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Piretanide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Piretanide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Piretanide.Investigational
AnisodamineAnisodamine may decrease the diuretic activities of Piretanide.Investigational
annamycinThe risk or severity of adverse effects can be increased when Piretanide is combined with annamycin.Investigational
AntipyrineAntipyrine may decrease the diuretic activities of Piretanide.Approved
ApocyninApocynin may decrease the diuretic activities of Piretanide.Investigational
ApramycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Apramycin.Experimental, Vet Approved
ApremilastApremilast may decrease the diuretic activities of Piretanide.Approved, Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Piretanide is combined with Arbekacin.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Piretanide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Piretanide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Piretanide.Investigational
AtracuriumPiretanide may decrease the neuromuscular blocking activities of Atracurium.Experimental, Investigational
Atracurium besylatePiretanide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the diuretic activities of Piretanide.Withdrawn
AzelastineAzelastine may decrease the diuretic activities of Piretanide.Approved
BalsalazideBalsalazide may decrease the diuretic activities of Piretanide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Piretanide.Approved, Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Piretanide.Approved, Investigational
BekanamycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Bekanamycin.Experimental
BenazeprilPiretanide may increase the hypotensive activities of Benazepril.Approved, Investigational
BendazacBendazac may decrease the diuretic activities of Piretanide.Experimental
BenorilateBenorilate may decrease the diuretic activities of Piretanide.Experimental
BenoxaprofenBenoxaprofen may decrease the diuretic activities of Piretanide.Withdrawn
BenzydamineBenzydamine may decrease the diuretic activities of Piretanide.Approved
BetamethasoneBetamethasone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
BevoniumBevonium may decrease the diuretic activities of Piretanide.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Piretanide.Experimental, Illicit, Withdrawn
BromfenacBromfenac may decrease the diuretic activities of Piretanide.Approved
BucillamineBucillamine may decrease the diuretic activities of Piretanide.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Piretanide.Approved
BufexamacBufexamac may decrease the diuretic activities of Piretanide.Experimental
BumadizoneBumadizone may decrease the diuretic activities of Piretanide.Experimental
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Piretanide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Piretanide.Approved, Illicit, Vet Approved
CanagliflozinCanagliflozin may increase the hypotensive activities of Piretanide.Approved
CandoxatrilPiretanide may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilPiretanide may increase the hypotensive activities of Captopril.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Piretanide.Illicit, Investigational, Vet Approved
CarprofenCarprofen may decrease the diuretic activities of Piretanide.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the diuretic activities of Piretanide.Experimental
CelecoxibCelecoxib may decrease the diuretic activities of Piretanide.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Piretanide.Approved, Investigational
ChloroquineChloroquine may decrease the diuretic activities of Piretanide.Approved, Vet Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the diuretic activities of Piretanide.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Piretanide.Approved, Investigational
CilazaprilPiretanide may increase the hypotensive activities of Cilazapril.Approved
CisatracuriumPiretanide may decrease the neuromuscular blocking activities of Cisatracurium.Approved, Experimental
Cisatracurium besylatePiretanide may decrease the neuromuscular blocking activities of Cisatracurium besylate.Approved
CisplatinPiretanide may increase the nephrotoxic activities of Cisplatin.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Piretanide.Approved, Investigational, Vet Approved
ClobetasolClobetasol may increase the hypokalemic activities of Piretanide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Piretanide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Piretanide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Piretanide.Approved
ClonixinClonixin may decrease the diuretic activities of Piretanide.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Piretanide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Piretanide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Piretanide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Piretanide.Approved
CurcuminCurcumin may decrease the diuretic activities of Piretanide.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Piretanide.Approved, Investigational, Vet Approved
CymarinThe risk or severity of adverse effects can be increased when Piretanide is combined with Cymarin.Experimental
D-LimoneneD-Limonene may decrease the diuretic activities of Piretanide.Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Daunorubicin.Approved
DecamethoniumPiretanide may decrease the neuromuscular blocking activities of Decamethonium.Approved
DeflazacortDeflazacort may increase the hypokalemic activities of Piretanide.Approved
DelaprilPiretanide may increase the hypotensive activities of Delapril.Experimental
dersalazinedersalazine may decrease the diuretic activities of Piretanide.Investigational
DeslanosideThe risk or severity of adverse effects can be increased when Piretanide is combined with Deslanoside.Approved
DesonideDesonide may increase the hypokalemic activities of Piretanide.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Piretanide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Piretanide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Piretanide.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Piretanide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Piretanide.Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Piretanide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Piretanide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Piretanide.Approved, Investigational
DibekacinThe risk or severity of adverse effects can be increased when Piretanide is combined with Dibekacin.Experimental
DiclofenacDiclofenac may decrease the diuretic activities of Piretanide.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the diuretic activities of Piretanide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Piretanide.Approved
DiflunisalDiflunisal may decrease the diuretic activities of Piretanide.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Piretanide.Approved, Investigational
DifluprednateDifluprednate may increase the hypokalemic activities of Piretanide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Piretanide is combined with Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Piretanide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Piretanide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Piretanide.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Piretanide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Piretanide.Approved
DobutamineDobutamine may increase the hypokalemic activities of Piretanide.Approved
DofetilidePiretanide may increase the QTc-prolonging activities of Dofetilide.Approved
Domoic AcidPiretanide may decrease the neuromuscular blocking activities of Domoic Acid.Experimental
Doxacurium chloridePiretanide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxorubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Doxorubicin.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Piretanide.Experimental
DroxicamDroxicam may decrease the diuretic activities of Piretanide.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Piretanide.Approved, Investigational
DuvelisibDuvelisib may decrease the diuretic activities of Piretanide.Investigational
E-6201E-6201 may decrease the diuretic activities of Piretanide.Investigational
EnalaprilPiretanide may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatPiretanide may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Piretanide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
EpirizoleEpirizole may decrease the diuretic activities of Piretanide.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Epirubicin.Approved
EquileninEquilenin may increase the hypokalemic activities of Piretanide.Experimental
EquilinEquilin may increase the hypokalemic activities of Piretanide.Approved
EstroneEstrone may increase the hypokalemic activities of Piretanide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Piretanide.Approved
EtanerceptEtanercept may decrease the diuretic activities of Piretanide.Approved, Investigational
EthenzamideEthenzamide may decrease the diuretic activities of Piretanide.Experimental
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Piretanide.Approved, Illicit
EtodolacEtodolac may decrease the diuretic activities of Piretanide.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the diuretic activities of Piretanide.Approved, Investigational
EtoricoxibEtoricoxib may decrease the diuretic activities of Piretanide.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Piretanide.Illicit, Vet Approved
Evening primrose oilEvening primrose oil may decrease the diuretic activities of Piretanide.Approved, Investigational
exisulindexisulind may decrease the diuretic activities of Piretanide.Investigational
FelbinacFelbinac may decrease the diuretic activities of Piretanide.Experimental
FenbufenFenbufen may decrease the diuretic activities of Piretanide.Approved
FenoprofenFenoprofen may decrease the diuretic activities of Piretanide.Approved
FenoterolFenoterol may increase the hypokalemic activities of Piretanide.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Piretanide.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may decrease the diuretic activities of Piretanide.Experimental
FeprazoneFeprazone may decrease the diuretic activities of Piretanide.Experimental
Ferulic acidFerulic acid may decrease the diuretic activities of Piretanide.Experimental
FloctafenineFloctafenine may decrease the diuretic activities of Piretanide.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Piretanide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Piretanide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Piretanide.Approved, Investigational
FlunixinFlunixin may decrease the diuretic activities of Piretanide.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the diuretic activities of Piretanide.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Piretanide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Piretanide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Piretanide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Piretanide.Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Piretanide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Piretanide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Piretanide.Approved
FlurbiprofenFlurbiprofen may decrease the diuretic activities of Piretanide.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Piretanide.Approved
Fluticasone propionateFluticasone propionate may increase the hypokalemic activities of Piretanide.Approved
FormestaneFormestane may increase the hypokalemic activities of Piretanide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Piretanide.Approved, Investigational
FoscarnetThe serum concentration of Foscarnet can be increased when it is combined with Piretanide.Approved
FosinoprilPiretanide may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinFosphenytoin may decrease the diuretic activities of Piretanide.Approved
FramycetinThe risk or severity of adverse effects can be increased when Piretanide is combined with Framycetin.Approved
GallaminePiretanide may decrease the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodidePiretanide may decrease the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GeneticinThe risk or severity of adverse effects can be increased when Piretanide is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Piretanide is combined with GENTAMICIN C1A.Experimental
GitoformateThe risk or severity of adverse effects can be increased when Piretanide is combined with Gitoformate.Experimental
GPX-150The risk or severity of adverse effects can be increased when Piretanide is combined with GPX-150.Investigational
GuacetisalGuacetisal may decrease the diuretic activities of Piretanide.Experimental
HalcinonideHalcinonide may increase the hypokalemic activities of Piretanide.Approved, Investigational, Withdrawn
HE3286HE3286 may increase the hypokalemic activities of Piretanide.Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may decrease the diuretic activities of Piretanide.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Piretanide.Approved, Illicit, Investigational
HigenamineHigenamine may decrease the diuretic activities of Piretanide.Investigational
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Piretanide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Piretanide.Approved, Illicit
Hygromycin BThe risk or severity of adverse effects can be increased when Piretanide is combined with Hygromycin B.Vet Approved
IbuprofenIbuprofen may decrease the diuretic activities of Piretanide.Approved
IbuproxamIbuproxam may decrease the diuretic activities of Piretanide.Withdrawn
IcatibantIcatibant may decrease the diuretic activities of Piretanide.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Idarubicin.Approved
ImidaprilPiretanide may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the diuretic activities of Piretanide.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Piretanide.Approved
IndobufenIndobufen may decrease the diuretic activities of Piretanide.Investigational
IndomethacinIndomethacin may decrease the diuretic activities of Piretanide.Approved, Investigational
IndoprofenIndoprofen may decrease the diuretic activities of Piretanide.Withdrawn
INNO-206The risk or severity of adverse effects can be increased when Piretanide is combined with INNO-206.Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Isepamicin.Experimental
IsoetarineIsoetarine may increase the hypokalemic activities of Piretanide.Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Piretanide.Approved
IsoxicamIsoxicam may decrease the diuretic activities of Piretanide.Withdrawn
IstaroximeIstaroxime may increase the hypokalemic activities of Piretanide.Investigational
IvabradinePiretanide may increase the arrhythmogenic activities of Ivabradine.Approved
KanamycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Kanamycin.Approved, Investigational, Vet Approved
KebuzoneKebuzone may decrease the diuretic activities of Piretanide.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Piretanide.Approved, Investigational
KetoprofenKetoprofen may decrease the diuretic activities of Piretanide.Approved, Vet Approved
KetorolacKetorolac may decrease the diuretic activities of Piretanide.Approved
Lanatoside CThe risk or severity of adverse effects can be increased when Piretanide is combined with Lanatoside C.Experimental
LeflunomideLeflunomide may decrease the diuretic activities of Piretanide.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Piretanide.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Piretanide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Piretanide.Approved
LicoriceLicorice may increase the hypokalemic activities of Piretanide.Approved
LisinoprilPiretanide may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the diuretic activities of Piretanide.Investigational
LithiumThe serum concentration of Lithium can be decreased when it is combined with Piretanide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Piretanide.Illicit
LonazolacLonazolac may decrease the diuretic activities of Piretanide.Experimental
LornoxicamLornoxicam may decrease the diuretic activities of Piretanide.Approved, Investigational
LoteprednolLoteprednol may increase the hypokalemic activities of Piretanide.Approved
LoxoprofenLoxoprofen may decrease the diuretic activities of Piretanide.Approved, Investigational
LumiracoxibLumiracoxib may decrease the diuretic activities of Piretanide.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the diuretic activities of Piretanide.Approved
MasoprocolMasoprocol may decrease the diuretic activities of Piretanide.Approved, Investigational
ME-609ME-609 may increase the hypokalemic activities of Piretanide.Investigational
Meclofenamic acidMeclofenamic acid may decrease the diuretic activities of Piretanide.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Piretanide.Approved
Mefenamic acidMefenamic acid may decrease the diuretic activities of Piretanide.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Piretanide.Vet Approved
MeloxicamMeloxicam may decrease the diuretic activities of Piretanide.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Piretanide.Experimental
MesalazineMesalazine may decrease the diuretic activities of Piretanide.Approved
MetamizoleMetamizole may decrease the diuretic activities of Piretanide.Investigational, Withdrawn
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Piretanide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Piretanide.Approved, Illicit
MethotrexateThe therapeutic efficacy of Piretanide can be decreased when used in combination with Methotrexate.Approved
Methyl salicylateMethyl salicylate may decrease the diuretic activities of Piretanide.Approved, Vet Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Metildigoxin.Experimental
MetocurinePiretanide may decrease the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodidePiretanide may decrease the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetrizamideThe risk or severity of adverse effects can be increased when Piretanide is combined with Metrizamide.Approved
MicronomicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Micronomicin.Experimental
MivacuriumPiretanide may decrease the neuromuscular blocking activities of Mivacurium.Approved
MizoribineMizoribine may decrease the diuretic activities of Piretanide.Investigational
MoexiprilPiretanide may increase the hypotensive activities of Moexipril.Approved
MofebutazoneMofebutazone may decrease the diuretic activities of Piretanide.Experimental
MometasoneMometasone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Piretanide.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the diuretic activities of Piretanide.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the diuretic activities of Piretanide.Approved
NabumetoneNabumetone may decrease the diuretic activities of Piretanide.Approved
NafamostatNafamostat may decrease the diuretic activities of Piretanide.Approved, Investigational
NaftifineNaftifine may decrease the diuretic activities of Piretanide.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Piretanide.Approved
NaproxenNaproxen may decrease the diuretic activities of Piretanide.Approved, Vet Approved
NCX 1022NCX 1022 may increase the hypokalemic activities of Piretanide.Investigational
NeamineThe risk or severity of adverse effects can be increased when Piretanide is combined with Neamine.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinPiretanide may decrease the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the diuretic activities of Piretanide.Approved
NetilmicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Netilmicin.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Piretanide.Experimental
NifenazoneNifenazone may decrease the diuretic activities of Piretanide.Experimental
Niflumic AcidNiflumic Acid may decrease the diuretic activities of Piretanide.Approved
NimesulideNimesulide may decrease the diuretic activities of Piretanide.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the diuretic activities of Piretanide.Investigational
NorepinephrineNorepinephrine may increase the hypokalemic activities of Piretanide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Piretanide.Approved, Illicit
OleandrinThe risk or severity of adverse effects can be increased when Piretanide is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Piretanide.Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Piretanide.Approved
OlopatadineOlopatadine may decrease the diuretic activities of Piretanide.Approved
OlsalazineOlsalazine may decrease the diuretic activities of Piretanide.Approved
OmapatrilatPiretanide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Piretanide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Piretanide.Approved
OrgoteinOrgotein may decrease the diuretic activities of Piretanide.Vet Approved
OuabainThe risk or severity of adverse effects can be increased when Piretanide is combined with Ouabain.Approved
OxaprozinOxaprozin may decrease the diuretic activities of Piretanide.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Piretanide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Piretanide.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the diuretic activities of Piretanide.Approved, Withdrawn
PancuroniumPiretanide may decrease the neuromuscular blocking activities of Pancuronium.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Piretanide.Approved
ParecoxibParecoxib may decrease the diuretic activities of Piretanide.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Paromomycin.Approved, Investigational
ParthenolideParthenolide may decrease the diuretic activities of Piretanide.Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Piretanide.Approved, Vet Approved
PerindoprilPiretanide may increase the hypotensive activities of Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Piretanide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Piretanide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Piretanide.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Piretanide.Experimental
PhenylbutazonePhenylbutazone may decrease the diuretic activities of Piretanide.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Piretanide.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may decrease the diuretic activities of Piretanide.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the diuretic activities of Piretanide.Approved, Investigational
PipecuroniumPiretanide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Pirarubicin.Investigational
PirbuterolPirbuterol may increase the hypokalemic activities of Piretanide.Approved
PirfenidonePirfenidone may decrease the diuretic activities of Piretanide.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Piretanide.Investigational
PiroxicamPiroxicam may decrease the diuretic activities of Piretanide.Approved, Investigational
PirprofenPirprofen may decrease the diuretic activities of Piretanide.Experimental
PlazomicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Plazomicin.Investigational
PlicamycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Plicamycin.Approved, Investigational, Withdrawn
PranoprofenPranoprofen may decrease the diuretic activities of Piretanide.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Piretanide.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Piretanide.Investigational
PrednicarbatePrednicarbate may increase the hypokalemic activities of Piretanide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Piretanide.Experimental, Investigational
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Piretanide.Approved
ProcaterolProcaterol may increase the hypokalemic activities of Piretanide.Approved, Investigational
ProglumetacinProglumetacin may decrease the diuretic activities of Piretanide.Experimental
PropacetamolPropacetamol may decrease the diuretic activities of Piretanide.Approved, Investigational
PropyphenazonePropyphenazone may decrease the diuretic activities of Piretanide.Experimental
ProquazoneProquazone may decrease the diuretic activities of Piretanide.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Piretanide is combined with Proscillaridin.Experimental
PTC299PTC299 may decrease the diuretic activities of Piretanide.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Puromycin.Experimental
PyrantelPiretanide may decrease the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuinaprilPiretanide may increase the hypotensive activities of Quinapril.Approved, Investigational
RamiprilPiretanide may increase the hypotensive activities of Ramipril.Approved
RapacuroniumPiretanide may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Piretanide.Approved
RescinnaminePiretanide may increase the hypotensive activities of Rescinnamine.Approved
ResveratrolResveratrol may decrease the diuretic activities of Piretanide.Approved, Experimental, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Ribostamycin.Approved, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Piretanide.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Piretanide is combined with Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Piretanide.Approved, Investigational
RocuroniumPiretanide may decrease the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the diuretic activities of Piretanide.Investigational, Withdrawn
SabarubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Sabarubicin.Investigational
SalbutamolSalbutamol may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
SalicylamideSalicylamide may decrease the diuretic activities of Piretanide.Approved
Salicylic acidSalicylic acid may decrease the diuretic activities of Piretanide.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Piretanide.Approved
SalsalateSalsalate may decrease the diuretic activities of Piretanide.Approved
SemapimodSemapimod may decrease the diuretic activities of Piretanide.Investigational
SeratrodastSeratrodast may decrease the diuretic activities of Piretanide.Approved
SerrapeptaseSerrapeptase may decrease the diuretic activities of Piretanide.Investigational
SisomicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Sisomicin.Investigational
Sodium phosphatePiretanide may increase the nephrotoxic activities of Sodium phosphate.Approved
SP1049CThe risk or severity of adverse effects can be increased when Piretanide is combined with SP1049C.Investigational
SpectinomycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Spectinomycin.Approved, Investigational, Vet Approved
SpiraprilPiretanide may increase the hypotensive activities of Spirapril.Approved
SRT501SRT501 may decrease the diuretic activities of Piretanide.Investigational
StreptomycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Streptomycin.Approved, Vet Approved
StreptozocinThe risk or severity of adverse effects can be increased when Piretanide is combined with Streptozocin.Approved
SuccinylcholinePiretanide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Piretanide.Approved, Investigational
SulfasalazineSulfasalazine may decrease the diuretic activities of Piretanide.Approved
SulindacSulindac may decrease the diuretic activities of Piretanide.Approved
SulpirideThe risk or severity of adverse effects can be increased when Piretanide is combined with Sulpiride.Approved, Investigational
SuprofenSuprofen may decrease the diuretic activities of Piretanide.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the diuretic activities of Piretanide.Experimental
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Piretanide.Approved
TarenflurbilTarenflurbil may decrease the diuretic activities of Piretanide.Investigational
TemocaprilPiretanide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the diuretic activities of Piretanide.Experimental
TenoxicamTenoxicam may decrease the diuretic activities of Piretanide.Approved
TepoxalinTepoxalin may decrease the diuretic activities of Piretanide.Vet Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Piretanide.Approved
TeriflunomideTeriflunomide may decrease the diuretic activities of Piretanide.Approved
Tiaprofenic acidTiaprofenic acid may decrease the diuretic activities of Piretanide.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Piretanide.Experimental
TinoridineTinoridine may decrease the diuretic activities of Piretanide.Investigational
TixocortolTixocortol may increase the hypokalemic activities of Piretanide.Approved
TobramycinThe risk or severity of adverse effects can be increased when Piretanide is combined with Tobramycin.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may decrease the diuretic activities of Piretanide.Approved
TolmetinTolmetin may decrease the diuretic activities of Piretanide.Approved
TopiramatePiretanide may increase the hypokalemic activities of Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Piretanide.Approved, Investigational
TrandolaprilPiretanide may increase the hypotensive activities of Trandolapril.Approved
TranilastTranilast may decrease the diuretic activities of Piretanide.Approved, Investigational
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
TribenosideTribenoside may decrease the diuretic activities of Piretanide.Experimental
TriptolideTriptolide may decrease the diuretic activities of Piretanide.Investigational
Trolamine salicylateTrolamine salicylate may decrease the diuretic activities of Piretanide.Approved
TubocurarinePiretanide may decrease the neuromuscular blocking activities of Tubocurarine.Approved
UlobetasolUlobetasol may increase the hypokalemic activities of Piretanide.Approved
ValdecoxibValdecoxib may decrease the diuretic activities of Piretanide.Investigational, Withdrawn
ValrubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Valrubicin.Approved
VecuroniumPiretanide may decrease the neuromuscular blocking activities of Vecuronium.Approved
VilanterolVilanterol may increase the hypokalemic activities of Piretanide.Approved
ZaltoprofenZaltoprofen may decrease the diuretic activities of Piretanide.Approved, Investigational
ZileutonZileuton may decrease the diuretic activities of Piretanide.Approved, Investigational, Withdrawn
ZofenoprilPiretanide may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the diuretic activities of Piretanide.Withdrawn
Zoptarelin doxorubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Zoptarelin doxorubicin.Investigational
ZorubicinThe risk or severity of adverse effects can be increased when Piretanide is combined with Zorubicin.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Yuji Chikaraishi, Yoshihisa Matsuda, Makoto Otsuka, "Amorphous piretanide, piretanide polymorphs, process for their preparation and their use." U.S. Patent US6096779, issued September, 1993.

US6096779
General References
Not Available
External Links
KEGG Drug
D01634
PubChem Compound
4849
PubChem Substance
46507197
ChemSpider
4683
ChEBI
32015
ChEMBL
CHEMBL349803
Therapeutic Targets Database
DNC001127
ATC Codes
C03CA03 — Piretanide

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP3.92BIOBYTE (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0914 mg/mLALOGPS
logP2.2ALOGPS
logP2.25ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)4.68ChemAxon
pKa (Strongest Basic)-0.62ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area109.93 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity93.68 m3·mol-1ChemAxon
Polarizability35.85 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9907
Blood Brain Barrier+0.6318
Caco-2 permeable-0.6466
P-glycoprotein substrateNon-substrate0.5237
P-glycoprotein inhibitor INon-inhibitor0.8026
P-glycoprotein inhibitor IINon-inhibitor0.6635
Renal organic cation transporterNon-inhibitor0.7657
CYP450 2C9 substrateNon-substrate0.7067
CYP450 2D6 substrateNon-substrate0.8032
CYP450 3A4 substrateNon-substrate0.5997
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6747
Ames testNon AMES toxic0.6433
CarcinogenicityNon-carcinogens0.6985
BiodegradationNot ready biodegradable0.9786
Rat acute toxicity1.8427 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.848
hERG inhibition (predictor II)Inhibitor0.5391
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-3980000000-dc67e28bf67c9f799108

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylethers
Direct Parent
Diphenylethers
Alternative Parents
Phenylpyrrolidines / Aminobenzenesulfonamides / Diarylethers / Aminobenzoic acids / Benzoic acids / Benzenesulfonyl compounds / Phenoxy compounds / Phenol ethers / Dialkylarylamines / Aniline and substituted anilines
show 11 more
Substituents
Diphenylether / Aminobenzenesulfonamide / 1-phenylpyrrolidine / Diaryl ether / Aminobenzoic acid / Aminobenzoic acid or derivatives / Benzenesulfonamide / Benzoic acid / Benzoic acid or derivatives / Benzenesulfonyl group
show 32 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 15:05